As a practice, crowd innovation has been around for more than 200 years. But only in the digital age has it become the hot topic it is now. And it cannot be implemented with a “one size fits all” approach, but needs significant planning.
In today’s world the question of third-party interests is of increasing importance as companies leave their footprint around the globe in different societies. How and to what degree should executives allow for these externalities?
The pharmaceutical industry is suffering. Expiring patents, increasing demands from regulators and decreasing healthcare budgets are putting companies under pressure, and the industry has to walk a narrow tightrope between keeping profitability up and quickly developing attractive medications....
Prism author Stefan Stern from the London-based Financial Times recently had a chance to catch up with Arthur D. Little's new global CEO, Michael Träm, who has just finished his first 200 days at the firm. In a long conversation Träm discussed the strengths of Arthur D.